FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the field of pharmaceuticals and can be used for treatment of a subject suffering from a gastrointestinal disease or disorder. For this purpose, a semi-solid composition is proposed, containing at least one cadotril in an amount of 5% wt./ wt. to 50% wt./wt. and at least one excipient in form of a liquid lipid and/or propylene glycol in an amount from 20% wt./wt. to 90% wt./wt., wherein at least one cadotril crystallises forming small crystals and the excipient in form of a liquid lipid constitutes at least one medium chain triglyceride or at least an oil containing medium chain triglycerides or mixtures thereof. The semi-solid composition therein is in form of a tablet or capsule, is capable of supporting its own weight and retaining the shape, and is also capable to flow under pressure. The group of inventions also relates to a dosage unit containing said semi-solid composition, to an application of the composition for treatment of a subject suffering from a gastrointestinal disease or disorder, and to a method for treatment using the dosage unit.
EFFECT: group of inventions provides improved characteristics of absorption efficiency, bioavailability and/or controlled release such as extended or delayed release.
14 cl, 5 dwg, 6 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
NEW IMPROVED RACECADOTRIL COMPOSITION | 2017 |
|
RU2745888C2 |
LIQUID ORAL PHARMACEUTICAL DOSAGE FORM CONTAINING HISTAMINE H2-RECEPTOR ANTAGONIST AND ANTACID | 2017 |
|
RU2761346C2 |
LIQUID ORAL PHARMACEUTICAL DOSAGE FORM | 2019 |
|
RU2810115C2 |
LIQUID ORAL PHARMACEUTICAL DOSAGE FORM | 2019 |
|
RU2783413C2 |
RACECADOTRIL LIPID COMPOSITIONS | 2014 |
|
RU2662069C2 |
LIPID COMPOSITIONS OF RACECADOTRIL | 2013 |
|
RU2632441C2 |
PHARMACEUTICAL COMPOSITION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME | 2018 |
|
RU2779262C2 |
USE OF ORGANIC EXTRACT OF CITRUS FRUITS WITH HIGH ANTIMICROBIAL ACTIVITY AS SYSTEM OF PRESERVING AGENTS IN LIQUIDS, EMULSIONS, SUSPENSIONS, CREAMS AND ANTACIDS | 2016 |
|
RU2714879C2 |
COMPOSITIONS CONTAINING UROLITINS | 2016 |
|
RU2754761C2 |
PHARMACEUTICAL COMPOSITION OF TAXOIDS | 2011 |
|
RU2603833C2 |
Authors
Dates
2021-07-16—Published
2017-01-09—Filed